A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection - Tenofovir Alafenamide (TAF) Children and Adolescents
Latest Information Update: 18 Mar 2026
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 30 Jan 2026 Status changed from active, no longer recruiting to recruiting.
- 29 Jul 2025 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.